Luxembourg, 21 September 2020



Scientific Committee on Health, Environmental and Emerging Risks (SCHEER)

Working Group on safety of breast implants in relation to anaplastic large cell lymphoma (BIA-ALCL)

Meeting date: 14 September 2020

Minutes

1. Welcome and apologies, approval of the agenda and declaration of interests

The Chair welcomed the participants; three apologies were received.

The agenda was adopted without change.

The Chair invited participants to declare any interest regarding matters on the agenda. None of the participants declared any interest conflicting with the matters on the agenda.

One member of the Working Group declared an interest that could be perceived as conflicting with the matters on the agenda: a research grant awarded by Allergan Pharmaceuticals International Ltd to the University (employer of that expert) to allow the conduct of an independent research into the pathogenesis of BIA-ALCL, starting today for one year. This declaration was included into the expert's annual Declaration of Interest form that will be published together with the preliminary Opinion. The declared interest was considered as not conflicting: it is concerning work on BIA-ALCL in general and not related to a specific producer, there will be no direct payment involved for the concerned expert and the start of that grant comes after the finalisation of the preliminary Opinion.

2. List of points discussed

2.1. Collection of data

The SCHEER WG checked data together with the Secretariat and some clarification was requested to the EC Library regarding the second search made.

2.2. Discussion of the draft opinion

The WG discussed the draft preliminary Opinion and contributions received from the members. New tasks have been allocated to the members. The chair and the rapporteur will present a final version during the SCHEER October plenary meeting taking into account last contributions by the members received by the end of September.

3. Any Other Business

The plan is to adopt the preliminary version during the plenary meeting and run a public consultation for 6 weeks (from 26 October until 7 December 2020), together with a **Hearing on 16 November 2020**. Members of the WG were invited to inform any interested person to **register for participation** (deadline 16 October) on the following website:

https://ec.europa.eu/health/scientific committees/events/ev 20201116 en

Delays may occur in view of the COVID-19 crisis limitations.
